leisure time -WSS

leisure time

author：fashion 2025-09-29 21:14:05 - browse：94

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： How housing is health care on Long Island

knowledge

WSS

Medicare Advantage today, explained in one chart

Copay coupons to count toward deductibles, after Biden court move

FDA approves updated Covid vaccines

How medical schools plan to diversify without affirmative action

WATCH: Why do bright lights make us see spots?

eGenesis tests gene

leisure time

leisure time

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Popular nasal decongestant doesn't actually relieve congestion

The cancer drug shortage isn’t new — and neither are the solutions

New brain studies show LSD's effects on the brain in full color

Bright Health sells Medicare Advantage business to Molina

Biotech venture capitalists face new demands from investors

Walensky prepares to leave CDC — and Congress — behind

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Wildfire smoke exposes gaps in outdoor worker protections

Food makers tried to stack nutrition panel with preferred experts

leisure time

Regeneron agrees to White House price limits on anti

eGenesis tests gene

Copay coupons to count toward deductibles, after Biden court move

eGenesis tests gene

Eli Lilly, Pfizer, and others want in on the online prescription market

Humana cuts profit projections as Medicare Advantage costs soar

focus

knowledge

focus

focus